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The electronic Medical Records and Genomics (eMERGE) (Phase I) network was
established in 2007 to further genomic discovery using biorepositories linked to the
electronic health record (EHR). In Phase II, which began in 2011, genomic discovery efforts
continue and in addition the network is investigating best practices for implementing
genomic medicine, in particular, the return of genomic results in the EHR for use
by physicians at point-of-care. To develop strategies for addressing the challenges
of implementing genomic medicine in the clinical setting, the eMERGE network is
conducting studies that return clinically-relevant genomic results to research participants
and their health care providers. These genomic medicine pilot studies include returning
individual genetic variants associated with disease susceptibility or drug response, as
well as genetic risk scores for common “complex” disorders. Additionally, as part
of a network-wide pharmacogenomics-related project, targeted resequencing of 84
pharmacogenes is being performed and select genotypes of pharmacogenetic relevance
are being placed in the EHR to guide individualized drug therapy. Individual sites within
the eMERGE network are exploring mechanisms to address incidental findings generated
by resequencing of the 84 pharmacogenes. In this paper, we describe studies being
conducted within the eMERGE network to develop best practices for integrating genomic
findings into the EHR, and the challenges associated with such work.
Keywords: genomics, electronic health records, incidental findings, implementation, genetic counseling, next
generation sequencing, pharmacogenetics
INTRODUCTION
The availability and reduced costs of high-density geno-
typing and genome sequencing technologies has accelerated
genomic discovery (Green et al., 2011). Genome-wide asso-
ciation studies (GWAS) have revealed numerous common
genetic variants that influence susceptibility to disease and
adverse drug reactions, as well as inter-individual variation in
quantitative traits and drug response (Manolio, 2013). Next-
generation sequencing has also enabled discovery of variants
associated with rare heritable diseases (Yang et al., 2013).
Assessing the utility and identifying best practices for inte-
gration of this new genomic knowledge into clinical practice
to improve patient care is now a major focus in the area
of translational genomics (Kullo et al., 2013; Manolio et al.,
2013).
The electronicMedical Records andGenomics (eMERGE) net-
work (see Supplementary Figure) was established in 2007 with
support from the National Human Genome Research Institute
(NHGRI) to further genomic discovery using biorepositories
linked to the electronic health record (EHR). The initial phase
(Phase I) of the eMERGE network included five sites: Group
Health Cooperative/University of Washington, Marshfield Clinic,
Mayo Clinic, Northwestern University, and Vanderbilt University.
The network was successful in leveraging the EHR to discover
new genetic associations including variants that influence traits
such as hematologic traits, lipid levels, Alzheimer disease, and
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electrocardiographic intervals among many others (Kullo et al.,
2010; Naj et al., 2011; Ding et al., 2012, 2013; Rasmussen-Torvik
et al., 2012; Crosslin et al., 2013). Phase II of eMERGE began in
August 2011 with the addition of Geisinger Health System and
Mount Sinai Medical Center to the network. In August 2012,
three pediatric sites joined the network: Children’s Hospital of
Philadelphia, and a joint membership of Cincinnati Children’s
Hospital Medical Center and Boston Children’s Hospital. As was
the case for Phase I sites, each new site has its own bioreposi-
tory linked to clinical phenotypes obtained from the EHR. While
continuing efforts at genomic discovery, eMERGE Phase II is also
investigating ways of incorporating genomics into the clinical set-
ting (Gottesman et al., 2013), in particular, the return of genomic
results in the EHR for use by healthcare providers at the point
of care.
Although the focus in Phase I of eMERGE was primarily on
genomic discovery efforts, eMERGE investigators also reviewed
what research findings should be considered for return to partic-
ipants (Fullerton et al., 2012). A return of results working group
was set up to address the types of genomic findings that might
be returned to patients or participants in the future. The genetic
data were generated from high-density genotyping arrays and
the return of results working group considered two main cate-
gories of genomic findings for return to participants. The first
related to common variants on these arrays that may have clinical
utility, e.g., Factor V Leiden, and hemochromatosis HFE vari-
ants. The second related to sex chromosome abnormalities such
as Klinefelter and Turner syndromes incidentally discovered on
signal intensity analysis of fluorescent data from the genotyp-
ing arrays. The investigators agreed that the potential to change
immediate medical care was an important criterion for consid-
ering return of a result. Based on this criterion, homozygosity
of single nucleotide polymorphism (SNP) rs6025 (R506Q, also
known as the Factor V Leiden mutation) and rs1800562 (HFE
C282Y, associated with hereditary hemochromatosis) were judged
to have the highest clinical relevance (Fullerton et al., 2012). Sex
chromosome abnormalities were also considered for return to
participants, although context, such as the age of the participant,
was felt to be an important factor. The working group summa-
rized these recommendations in a position paper (Fullerton et al.,
2012).
In Phase II of eMERGE, genomic discovery efforts continue,
but the focus has expanded to include clinical implementa-
tion of genomic data. In addition to high-density genotype
data in a large number of patients (see Supplementary Table)
(Gottesman et al., 2013), targeted next-generation sequencing
data of 84 ‘very important pharmacogenes’ (VIPs) will be avail-
able for nearly 10,000 patients across the network as part of
the eMERGE PGx project. Genetic data being considered for
return to participants include SNPs of medical or pharmaco-
genetic relevance, genetic risk scores for common diseases as
well as pharmacogenomic variants, and clinically actionable inci-
dental findings related to next-generation sequencing of 84VIPs
(e.g., RYR1 and CACNA1S genes associated with malignant
hyperthermia). Candidate variants for possible return to par-
ticipants and incorporation into EHR, will be validated in a
CLIA-certified laboratory. Clinical integration of genomic data
is being explored with active examination of the ethical, legal,
and social implications of such integration for both patients and
clinicians.
To start addressing the opportunities and challenges in return-
ing genomic results in the clinical setting, each site is conduct-
ing genomic medicine pilot projects to return clinically relevant
genomic results to participating patients and their health care
providers. Additionally, pharmacogenomic information is being
placed preemptively in the EHR as part of the network-wide
eMERGE PGx project. In this article, we review the current sta-
tus of the genomic medicine pilot projects at each eMERGE site
and the challenges associated with such work. The aim of each
project and the genetic variants being considered for return are
summarized in Table 1. The categories of genomic results being
considered for return to patients in eMERGE II include indi-
vidual or multiplexed SNPs that influence disease susceptibility
or drug responses. The following sections provide an overview
of the activities in eMERGE II related to return of results in
these pilot genomic medicine implementation projects. A sep-
arate manuscript is planned to address return of results in the
setting of genomic discovery.
INDIVIDUAL SNPs
Individual SNPs associated with disease risk or of pharma-
cogenomic relevance are being considered for return of results
studies within the eMERGE network, and results of this type
are being returned in two eMERGE II pilot studies. A variant
in the apolipoprotein L1 (APOL1) gene that is associated with
non-diabetic chronic kidney disease (CKD) in patients of African
American ancestry (Tzur et al., 2010; Parsa et al., 2013) is being
returned in a pilot study at the Mount Sinai Medical Center.
To understand processes and the impact of implementing a
screening and decision support system for risk of non-diabetic
CKD in African American patients with hypertension and/or
family history of renal failure, ∼40 participants will be genotyped
for three risk variants in exon 6 of APOL1. A catalog of current
evidence-based guidelines for the management of hyperten-
sion and chronic kidney disease will group the participants
into three renal care advice message categories including (i)
evaluation of CKD, (ii) identification of CKD progression, and
(iii) prevention of CKD progression. In-depth, audio-recorded
qualitative interviews are being conducted with patients before
and after they receive their APOL1 results. Analysis of the
transcribed interviews will inform the design of the clinical
decision support and patient education materials, and the
design of quantitative questionnaires for use in a planned
larger study of returning APOL1 results to patients in clinical
practice.
At Northwestern University, investigators are following up on
the recommendations from the Return of Results workgroup in
eMERGE I to include return of potentially actionable findings by
reconsenting 150 biobank participants who were genotyped dur-
ing Phase I of eMERGE. Participants will undergo CLIA-certified
genotyping of the Factor V Leiden mutation and the hereditary
hemochromatosis HFE mutations (C282Y and H63D). Results
will be deposited in the EHR and available to physicians. Study
participants will be informed of their results via a letter that will
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Table 1 | Summary of the eMERGE genomic medicine pilot projects.
Site Study aim Variants Results returned by EHR integration
Essentia Health Evaluate genetic markers for
increased risk of age-related
macular degeneration (AMD) in
the clinical setting
Five variants in CFH, one variant
in ARMS-2, one variant in C3, and
one variant in ND2, will be
genotyped and results returned
Optometrist Provider is notified
electronically that genetic
results and risk score are
available in patients’ EHR
Geisinger Health System (1) Incorporate IL28B genotyping
and genotype-guided therapy into
the standard treatment protocol
for chronic hepatitis C virus
infection
(2) Develop a clinical WGS
sequencing program.
(3) Genetic risk score to identify
patients for AAA screening
(1) Two variants in IL28B
associated with treatment
response
(2) Identify causal variants based
on indication for testing as well as
clinically actionable incidental
findings
(3) Multi-SNP panel
(1) Hepatologist
(2) Clinical geneticist and
genetic counselor
(3) Patient’s provider,
preventive care team
(1) Electronic Order Set
(2) Genomic test report
in laboratory section;
certain variants (e.g.
pharmacogenetic) will
have CDS tied to
computerized order entry
(3) CDS tied to
preventive health care
reminder system
Group Health
Cooperative and
University of Washington
Six genes with highly penetrant
variants will be sequenced and
confirmed pathogenic variants will
be returned to participants
Pathogenic variants in CACNA1C
and RYR1 (malignant
hyperthermia), KCNH2 and
SCN5A (long QT syndrome),
RYR2 (catecholaminergic
polymorphic ventricular
tachycardia), and LDLR
(hyperlipidemia)
Genetic counselor or
medical geneticist
Results placed in the
EHR
Mayo Clinic Disclosure of genomic risk of
myocardial infarction using a
genetic risk score integrated into
the Framingham risk score
28 SNPs associated with
coronary heart disease in prior
GWAS are genotyped in a CLIA
laboratory and returned
Genetic counselor using
an EHR-based tool
followed by visit with a
preventive
cardiologist/internist
An EHR-based tool is
used to communicate
genomic risk. Genotyping
results are placed in the
EHR
Icahn School of Medicine
at Mount Sinai
Evaluate implementation of a
screening and decision support
system for risk of non-diabetic
kidney disease in African
Ancestry patients with
hypertension and/or family history
of renal failure
APOL1 risk allele status Genetic counselor or
primary care provider
Placed in the EHR and
linked to CDS
Northwestern University Assess the impact and use of
genomic results on clinical care
by both physicians and patients,
to evaluate the use and impact of
physician support documents and
best practice alerts in the EHR for
genomic results, and to evaluate
the non-clinical care impact of
genomic results on patients
Variants in FV, FII, and HFE
mutations (C282Y and H63D)
Physician with referral to
study genetic counselor
available
Genomic test results
available in laboratory
section of EHR;
Physicians alerted when
results received; CDS
developed to alert if risk
is present; Contextual
links to patient and
physician information
resources
Vanderbilt University Three major outcomes are being
assessed including the efficacy of
pharmacogenomics testing in
reducing adverse drug events,
physician uptake, and patients’
knowledge and reaction
Fourteen actionable genetic
variants that include: CYP2C19
*2-*8 (clopidogrel), CYP2C9
*2-*3, VKORC1 rs9923231
(warfarin), SLCO1B1 *5
(simvastatin), and TMPT *1-*3
(thiopurines)
Ordering physician Genomic test results
available in laboratory
section of EHR, Patient
Summary, and in Patient
Portal
Children’s Hospital of
Philadelphia
The main focus is on prevention
of potentially life-threatening drug
adverse events
HLA-B*1502 (carbamazepine
induced Stevens-Johnson
syndrome) and TPMT
(thiopurines) variants
Ordering physician Results shared with
providers and placed in
the EMR
(Continued)
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Table 1 | Continued
Site Study aim Variants Results returned by EHR integration
Cincinnati Children’s
Hospital and Boston
Children’s Hospital
Explore parents’ responses to
their children’s research results
Cincinnati Children’s Hospital will
return 21 variants of CYP2D6 test
results while Boston Children’s
Hospital will return hypothetical
CYP2D6 results
Genetics clinical nurse
specialist
Results shared with
primary care providers
but not placed in EHR
AAA, abdominal aortic aneurysm; CDS, clinical decision support; GWAS, genome-wide annotation studies.
be sent by post or accessible via an online patient web-portal
called MyChart). Participants will also complete a baseline survey
and follow-up surveys at 1 and 6 months after receiving results.
Physicians and participants will also have the opportunity to dis-
cuss the results during an appointment or be referred to a study
genetic counselor. Semi-structured interviews will be conducted
with physicians after results are returned to patients and clinical
decision support has been triggered in the EHR. The impact
and use of genomic results on both physicians and patients will
be assessed, as will the use and impact of physician support
documents and best practice alerts in the EHR for genomic
results.
PHARMACOGENETIC VARIANTS
At the Vanderbilt University site, 14 pharmacogenetic vari-
ants including: CYP2C19 ∗2–∗8 (clopidogrel), CYP2C9 ∗2–∗3,
VKORC1 rs9923231 (warfarin), SLCO1B1 ∗5 (simvastatin), and
TMPT ∗1–∗3 (thiopurines) will be genotyped in their study
population. Vanderbilt University has conducted a number of
research studies to assess the efficacy of the Pharmacogenomic
Resource for Enhanced Decision in Care and Treatment
(PREDICT) program in reducing adverse drug events, physi-
cian uptake, and patients’ knowledge and attitudes toward such
testing. Physician surveys and structured interviews have been
performed. Interviews have been conducted in the following
groups of patients who have been through the interventional car-
diology clinic: (i) no medication change following PREDICT, (ii)
a change in clopidogrel medication dosing, (iii) change in statin
medication dosing, and (iv) not enrolled in PREDICT. Results of
these surveys and interviews are awaited.
At the University of Washington-Group Health site,
pathogenic variants in six highly penetrant pharmacogenes
will be genotyped in ∼450 participants. These variants include
risk alleles in CACNA1C (malignant hyperthermia), RYR1
(malignant hyperthermia), KCNH2 (long QT syndrome),
SCN5A (long QT syndrome), RYR2 (catecholaminergic poly-
morphic ventricular tachycardia), and LDLR (hyperlipidemia).
Results are expected to be returned through the Department
of Clinical Genetics with appropriate counseling and subse-
quent documentation in the EHR. Patients will be surveyed
regarding their experience. Healthcare providers will be sur-
veyed to assess their use of genetic information in EHR,
ease of use, completeness of information in the EHR, and
whether any other resources are needed. Additionally, feasibility
of implementing genomic clinical decision support will be
assessed by interviews with patients and healthcare providers
to guide development and testing of prototype interfaces
for the EHR.
In a clinical implementation project at Geisinger Health
System, all newly diagnosed patients with chronic HCV are
genotyped in a CLIA laboratory for two variants in the inter-
leukin 28B gene (IL28B) that influence treatment response and
can influence medication choice. A genotype-guided treatment
decision tree was created in consultation with expert clini-
cians and an electronic order set was implemented in the
EHR to insure that all eligible patients underwent testing.
Genotype results for any participant who is prescribed inter-
feron alpha and ribavirin for chronic HCV infection are placed
in the EHR and are available to hepatologists initiating treat-
ment. The economic impact of use of these variants is being
studied.
Investigators at Children’s Hospital of Philadelphia are work-
ing on developing tools to engage local practitioners in targeted
intervention projects trialing in-house web-based software that
integrates with the EHR (Fiks et al., 2013). This new tool can
be used to query the institutional biobank as well. So far, 515
patients have been genotyped for HLA-B∗1502 which is associ-
ated with risk of developing Stevens-Johnson syndrome following
use of carbamazepine (Chen et al., 2011), in addition to 318
patients genotyped for TPMT in patients that may be treated with
thiopurines.
Investigators at Cincinnati Children’s Hospital Medical Center
are studying the return of CYP2D6 variants in pediatric patients
in the content of codeine response, and returning these results
to the parents. Variants of CYP2D6 are genotyped using Taqman
and long polymerase chain reaction for full gene deletion and
duplication. At the time results are returned to parents, they
complete a telephone survey about their reactions and plans
to share the actual results, and their anticipated preferences
regarding receiving hypothetical incidental findings. Follow-up
telephone calls are being conducted at 3 and 12 months post-
result disclosure to learn how results were used. A subset of
parents are also participating in qualitative interviews to further
explore their reactions and perceptions to receiving their chil-
dren’s CYP2D6 results. Although results will not be placed in
the EHR, the researchers are asking parents for permission to
share the results with their child’s primary care providers and
will evaluate primary care providers’ reactions to receiving the
results. At the Boston Children’s Hospital site, the same study,
including the same survey and qualitative interviews, is being car-
ried out but using hypothetical, not actual CYP2D6 results, and
without the follow-up telephone calls. Providers will be surveyed
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about the perceived utility of pharmacogenomics research results
in their practice. Between the two sites in Cincinnati and Boston,
parents of 400 children will be enrolled. To date, Cincinnati
Children’s has returned 48 children’s CYP2D6 results to parents
and has recontacted 21 parents, all of whom have given per-
mission to share the results with their children’s primary care
providers.
GENETIC RISK SCORES
Genetic findings of clinical relevance from high-density geno-
typing arrays include numerous common alleles that influence
disease susceptibility. Because most individual variants have
modest effect sizes, investigators are exploring the utility of
combining the risk variants into genetic risk scores. At the
Marshfield/Essentia Health site, a genetic risk score for age-related
macular degeneration (AMD) is calculated based on five vari-
ants in CFH, one variant in ARMS-2, one variant in C3 and
one variant in ND2. Individuals (n = 100) attending optome-
try clinics are genotyped for these variants (Haines et al., 2005)
and a genetic risk score is calculated and incorporated into the
EHR by optometrists. Overall risk will be calculated from the
genotypes and the patient’s smoking status. The results will be
shared with the study participants and a telephone survey will
be conducted. The participating clinicians will be interviewed
after reviewing these results. Recruitment for this study began in
June 2013.
At Mayo Clinic, investigators are conducting the Myocardial
Infarction Genes (MI-GENES) clinical trial, a pilot study of com-
municating genetic risk for coronary heart disease (CHD), the
leading cause of death in the US. Patients at intermediate risk
for CHD based on conventional risk factors will undergo geno-
typing of ∼28 SNPs that are associated with CHD independent
of lipid or blood pressure levels, in a CLIA laboratory (Deloukas
et al., 2013). Study participants will be randomized to receive
a Framingham risk score or a modified Framingham risk score
that incorporates a genetic risk score based on the genotyping
results. The genetic risk scores will be placed in the EHR and
an EHR-based pictogram will be used to assist in discussing
genomic risk of CHD. Patients in the study will be followed for
at least 6 months to assess the extent to which there are differ-
ences in diet, physical activity, and other lifestyle modifications
associated with the communication of CHD-related genomic risk
information. Participants will also be evaluated for psychosocial
and behavioral changes. Recruitment for MI-GENES started in
October 2013.
At Geisinger Health System, investigators are combining clin-
ical risk factors and genomic information to develop a risk score
for abdominal aortic aneurysm (AAA), a leading cause of death
in older men (Kent et al., 2010; Kuivaniemi et al., 2012). The
goal is to develop strategies for population screening that combine
genetic susceptibility variants with clinical risk factor data mined
from EHR. Patients in the Geisinger MyCode biobank (Gerhard
et al., 2013; Gottesman et al., 2013) will be genotyped for vari-
ants known to be associated with AAA (Kuivaniemi et al., 2013)
and this information used to create a risk score that will then be
evaluated in the Geisinger patient population after performing
abdominal ultrasonography examination.
TARGETED NEXT-GENERATION SEQUENCING
The eMERGE pharmacogenomics (PGx) project is using tar-
geted sequencing of 84 pharmacogenes to initiate a multi-site
test of the concept that genomic sequence information can be
coupled to EHRs for use in the clinical setting (Gottesman
et al., 2013). The PGRNseq uses a reagent to “capture” exonic
sequences of 84 genes important in pharmacokinetic or phar-
macodynamics processes for sequencing on next-generation plat-
forms. Genotypes of established pharmacogenomics utility that
influence use of simvastatin, clopidogrel, and warfarin will be
confirmed in a CLIA environment and be placed pre-emptively
in the EHRs of patients who are “at risk” of receiving these
drugs.
Sequence information will also be generated for six genes
for which the American College of Medical Genetics and
Genomics (ACMG) guidelines suggest returning known
or expected pathogenic variants given the association with
highly penetrant actionable disorders (Green et al., 2013)
(Table 2). These include genes associated with long QT
syndrome genes (KCNH2 and SCN5A), malignant hyperther-
mia (RYR1 and CACNA1S), hypercholesterolemia (LDLR),
and catecholaminergic polymorphic ventricular tachycardia
(RYR2).
ACMG guidelines emphasize return of mutations in these
genes that are known to be pathogenic but also suggest return-
ing novel mutations that are “expected” to be pathogenic. The
recommendations have stimulated considerable debate (Green
et al., 2013), and in particular, whether patient preferences can
or should be incorporated into the return of results pipeline has
been highlighted (Allyse and Michie, 2013). While the ACMG
recommendations do not apply to research participants, mem-
bers of the eMERGE network’s Consent, Education, Regulation
and Consultation (CERC) workgroup have weighed in with
concerns about the scope of the ACMG position (Burke and
Grefenstette, 2013; Ross et al., 2013). The mechanisms for
Table 2 | Pharmacogenes being sequenced in the eMERGE PGx
project and on the ACMG incidental finding list (Green et al., 2013).
Gene Phenotype Inheritance* Variants to
report**
RYR2 Catecholaminergic
polymorphic ventricular
tachycardia
AD KP
KCNQ1
KCNH2
SCN5A
Romano-Ward long QT
syndrome types 1, 2, and
3, Brugada syndrome
AD KP and EP
LDLR Familial
hypercholesterolemia
SD KP and EP
RYR1
CACNA1S
Malignant hyperthermia
susceptibility
AD KP
*SD, semi-dominant inheritance; AD, autosomal dominant.
**EP, expected pathogenic, sequence variation is previously unreported and is of
the type that is expected to cause the disorder. KP, known pathogenic variants.
Adapted from the ACMG Policy Statement (Green et al., 2013).
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whether and how to return incidental findings are being eval-
uated at each site. Several sites, in consultation with respec-
tive IRBs, are considering confirming pathogenic incidentally
found variants for example in RYR1 and CACNA1S, with an
orthogonal genotyping method. This would be followed by
inviting the study patient to a genetic counseling session dur-
ing which the option of knowing the research results with
confirmation in a CLIA lab will be discussed. Table 3 sum-
marizes the approach of the various sites toward returning
incidental findings generated as part of the eMERGE PGx
project.
WHOLE GENOME/EXOME SEQUENCING
Whole genome and exome sequencing are being increasingly uti-
lized in the clinical setting (Yang et al., 2013). Although less
than 2% of adults appear to have relevant actionable incidental
findings from whole exome sequencing (Dorschner et al., 2013)
whether to return such findings is an important topic of debate
(Green et al., 2013), particularly in the context of preserving
patient autonomy and confidentiality (Klitzman et al., 2013).
Institutional committees with diverse expertise will need to adapt
guidelines proposed by the ACMG to determine whether and
how these can be applied locally, which results will be reported
through local EHRs and what format these reports will take.
The Clinical Sequencing Exploratory Research (CSER) consor-
tium is also actively investigating return of results in studies
utilizing whole genome or whole exome sequencing (https://
cser-consortium.org). Several of the eMERGE sites have con-
ducted pilot studies of whole genome/exome sequencing in
the clinical setting. For example, at Geisinger Health System,
investigators are developing a laboratory report that summa-
rizes results of whole genome sequencing in individuals with
intellectual disability and normal chromosomal microarray that
have been recruited along with their parents to undergo whole
genome sequencing to identify an underlying genetic etiology.
Causal variants and incidental findings (from the ACMG list)
will be validated using Sanger sequencing. All patients will be
informed about the results and undergo counseling. Qualitative
Table 3 | Return of results related to the eMERGE pharmacogenomics (PGx) projects at each of the eMERGE network sites.
Site Genetic variants to be returned and placed in
the EHR
Return of incidental findings of known clinical
significance
Geisinger Health System Pharmacogenetic variants relevant to clopidogrel,
warfarin, and simvastatin
IFs will be returned only if they have clear clinical
significance.
Group Health Cooperative and University
of Washington
PGx variants for carbamazepine sensitivity are
approved for inclusion in the EHR
IFs will be returned by a clinical geneticist and this
information would be placed in the EHR at the time
of the encounter.
Marshfield Clinic Pharmacogenetic variants relevant to clopidogrel,
warfarin, and simvastatin
IFs will be returned only if they are clinically
relevant based on input from a physician, clinical
geneticist and/or medical specialist in that area of
expertise.
Mayo Clinic Pharmacogenetic variants relevant to clopidogrel,
warfarin, and simvastatin
IFs will be reviewed by a multidisciplinary group
prior to return.
Icahn School of Medicine at Mount Sinai 4 NYS/CLIA-approved genetic variants relevant to
clopidogrel, warfarin, and simvastatin
IFs will not be returned.
Northwestern University Pharmacogenetic variants relevant to clopidogrel,
warfarin, and simvastatin
IFs will not be returned.
Vanderbilt University 11 PGx variants relevant to clopidogrel, warfarin,
and simvastatin were already reported
IFs will not be returned.
Children’s Hospital of Philadelphia Variants in several pharmacogenes will be
returned: CYP2D6 and UGT2B7 (codeine), CRHR1
(fluticasone propionate), UGT1A4 (lamotrigine),
KCNH2 (loratadine), SLCO2B1 (montelukast,
CYP2D6, ABCB1, OPRM1, COMT, and UGT2B7
(morphine), CYP2C19 and AHR (omeprazole),
ABCB1 (ranitidine), ADRB2 (salbutamol), BDNF
(sertraline), and IL28B and HLA-DR/DQ (interferon
response variants)
IFs will be returned only if they are clinically
relevant based on input from a physician, clinical
geneticist and/or medical specialist in that area of
expertise.
Cincinnati Children’s Hospital (CCHMC)
and Boston Children’s Hospital (BCH)
CCHMC: Genetic variants in CYP2D6
pre-emptively placed in EMR for children at risk for
having surgery. PGx variants placed in EMR at
point of care include those relevant for warfarin,
thiopurines, tricyclic antidepressants and some
SSRIs. BCH: Genetic variants relevant to warfarin
CCHMC: IFs need to be reviewed and approved by
IRB before return and placement in EHR.
BCH: IFs will be reviewed by Informed Cohort
Oversight Board (ICOB) and appropriate action will
be determined.
IFs, incidental findings.
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data from interviews will be collated and used to improve this
process.
INTEGRATION OF GENOMIC FINDINGS INTO THE EHR
A recent theme issue of Genetics in Medicine addressed the issues
related to integrating genomic findings into the EHR with linkage
to clinical decision support at point of care (Kannry andWilliams,
2013). Lack of standardized nomenclature for genetic variants is a
major hurdle to creating automated decision support. Currently,
several groups, including the Health Level 7 Genomics Work
Group, are attempting to address this challenge. Additional chal-
lenges relate to a number of ethical, legal, and social implications
that have been reviewed elsewhere (Hartzler et al., 2013; Hazin
et al., 2013). These include uniform provision of genomic CDS
to prevent worsening of disparities in healthcare, education of
patients and providers, determining which genomic information
to include in the EHR, managing incidental findings, privacy and
documentation, storage and reinterpretation of genomic data and
the results of stakeholder engagement in making these determina-
tions. Education of patients and care providers will be necessary
to facilitate the process of return of genomic results. The CERC
Work Group in eMERGE has begun to address some of the
education issues through jointly developing education materi-
als and a website for patient information (www.myresults.org)
and contributing to evaluation of online pharmacogenomics
information for physicians. The CERC Working Group also
has collaborative interactions with the CSER and Return of
Results consortia.
SUMMARY
Genomic technology has advanced greatly through the last
decade. As we attempt to implement genomic medicine,
many challenges arise, including the need to develop suitable
approaches to return results and to deal with incidental find-
ings. We have summarized activities within the eMERGE network
that are related to returning genomic results in the EHR setting
and also with the return of incidental findings. Initial experiences
within the eMERGE network highlight the need for additional
studies that address the issues related to disclosure of results from
genomic implementation studies. Ongoing work in the eMERGE
network will provide important insights into best practices for
returning genomic results and dealing with incidental findings
using the EHR.
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